Prana receives first orphan drug designation from the FDA for the treatment of Multiple System Atrophy
Category: Investor Announcement
Prana Biotechnology BSC Presntation 20180107 FINAL
Prana's Chief Medical Officer Dr David Stamler, MD will present at the Biotech Showcase in San Francisco on Monday 7th January, US Pacific Standard Time.
Prana Biotechnology has today announced that it has entered into a securities purchase agreement for a lead investment by Boston based Life Biosciences LLC (“Life Biosciences”) to raise up to approximately A$44.5 million
2018_11_16 AGM Presentation 2018
Prana invites investors unable to attend the Company’s Annual General Meeting to participate via teleconference.
PBT434 prevents alpha-synuclein aggregation, preserves neurons, reduces glial cell inclusions and slows motor dysfunction in an animal model of Multiple System Atrophy
Prana’s PBT434 prevents neuronal loss in a new model of neurodegeneration
Prana Biotechnology is pleased to announce the first cohort of volunteers in its Phase I clinical trial have been administered PBT434, an experimental drug under investigation for the treatment of Parkinsonian diseases.